Trial · NCT04586023
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Annualized Relapse Rate (ARR) | Minimum of 96 weeks | |
| Secondary | Time to Onset of Composite 12-week Confirmed Disability Progression (cCDP12) | Minimum of 96 weeks | |
| Secondary | Time to Onset of Composite 24-week Confirmed Disability Progression (cCDP24) | Minimum of 96 weeks | |
| Secondary | Time to Onset of 12-week Confirmed Disability Progression (CDP12) | Minimum of 96 weeks | |
| Secondary | Time to Onset of 24-week Confirmed Disability Progression (CDP24) | Minimum of 96 weeks | |
| Secondary | Total Number of T1 Gadolinium Enhancing (Gd+) Lesions, New and/or Enlarging T2-weighted Lesions, as Detected by Magnetic Resonance Imaging (MRI) | Baseline, Weeks 12, 24, 48 and 96 | |
| Secondary | Percentage Change in Total Brain Volume From Week 24, as Assessed by MRI | From Week 24 to Week 96 | |
| Secondary | Change in Participant-reported Physical Impacts of Multiple Sclerosis (MS), Measured by the Multiple Sclerosis, Impact Scale (29-Item), Version 2 (MSIS-29 v2) Physical Scale | Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and 96 | |
| Secondary | Time to Onset of 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT) Score | Minimum of 96 weeks | |
| Secondary | Percent Change From Baseline to Week 48 in the Concentration of Blood Neurofilament Light (NfL) Chain | Baseline, Week 48 | |
| Secondary | Time to Onset of Composite 12-week Confirmed Progression Independent of Relapse Activity (cPIRA12) | Minimum of 96 weeks | |
| Secondary | Percentage of Participants With Adverse Events (AEs) | Up to approximately 4.5 years | |
| Secondary | Plasma Concentrations of Fenebrutinib at Specified Timepoints | Up to approximately 4.5 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04586023/registered